Oric Pharmaceuticals, Inc. Common Stock
ORICOric Pharmaceuticals, Inc. is a biotechnology company focused on developing targeted therapies for cancer, with an emphasis on overcoming resistance to existing treatments. Founded with the goal of advancing precision medicine, Oric aims to address unmet needs in oncology by developing novel agents that improve patient outcomes.
Company News
The precision oncology market is projected to grow from $110 billion to $225.65 billion by 2032, driven by Big Pharma's race to acquire registration-ready assets ahead of a $170 billion patent cliff through 2030. Several biotech companies are advancing promising clinical programs: Oncolytics Biotech strengthened its leadership team for pelareorep...
ORIC Pharmaceuticals presented promising Phase 1b trial results for enozertinib, demonstrating strong systemic and CNS activity in NSCLC patients with EGFR exon 20 mutations, with high objective response rates and a competitive safety profile.
ORIC Pharmaceuticals presented promising Phase 1b trial results for enozertinib, a potential treatment for non-small cell lung cancer (NSCLC) with EGFR mutations, showing strong systemic and CNS activity with favorable safety profile.
ORIC Pharmaceuticals published research in Cancer Research detailing enozertinib, a highly selective brain-penetrant EGFR inhibitor targeting non-small cell lung cancer mutations, demonstrating potential for treating intracranial disease.
ORIC Pharmaceuticals, Inc. announced the grant of 39,100 non-qualified stock options and 6,500 restricted stock units to three new non-executive employees. The grants were made as inducements to employment in accordance with Nasdaq rules.
